Life Sciences Archive » September, 2018

Life Sciences - September, 2018

280 articles

• Supreme Court Cheat Sheet: 8 Cases To Watch
• Health Hires: Carlton Fields, Crowell & Moring, GCs
• SEC Accuses Drugmaker of Venomous Deceptions
• FDA Halts Imports From Chinese Drug Co. Over Impurities
• PE Firms Let Out Of Zimmer Investors' Stock-Drop Suit
• Compounding Pharmacy, Owner Ink $1.2M Deal In FCA Case
• Swimmer Cleared Of Doping After Meds Found Contaminated
• 9 Firms To Guide IPOs Totaling $779M To Launch October
• Sensipar Exclusivity Expires, Ending Amgen's DC Circ. Fight
• Walgreens, Kroger Have No Right To Sue Over Remicade: J&J
• Fed. Circ. Partly Revives Bard Medical Device Patents
• Skadden, Latham Lead $152.2M In Biotech, Tech Startup IPOs
• Opioid Task Force Arrests 76 After Raid On Tribal Land
• Stryker Settles SEC's Latest FCPA Claims For $7.8M
• Ex-Salix CFO Pays $1M To End Claims He Misled Investors
• Teva Revives Patent Fight After FDA OKs Lilly's Migraine Drug
• The Evolution Of Conspiracy Personal Jurisdiction
• Dismissing FCA Cases: The Granston Memo In Action
• Kessler Topaz Tapped To Lead Celgene Investor Suit
• KDB Expands Intellectual Property Force With 5 Hires
• Bull Stud Co. Wins $5M Fees, Costs In Semen-Sorting Row
• 6th Circ. Revives Esperion Investor Suit Over Cholesterol Drug
• Texas Man Still Barred From Selling 'Miracle' Supplement
• Five Cos. Price IPOs Totaling $483M Led By 3 Biotech Firms
• Pa. Doc's TCPA Row With Sanofi Timely, 3rd Circ. Told
• ActiveCare Ch. 11 Sale Delayed Amid Potential Claim Issues
• Construction Co. Gets Army Facility Contract Suit Trimmed
• Lilly Migraine Med's Uncertain Future Kills Teva's Patent Suit
• Ariosa Prior Art Appeal Relies On Old Law, Illumina Says
• Pa. Can't Hide Medical Marijuana Permit Reviewers' Names
• Suit From CVS, Others To End Opioid Tribal Court Case Axed
• Fidelity Leads Ultrasound Co.'s $250M Funding Round
• Al Jazeera Must Produce Docs In Doping Documentary Suit
• How Corporate Reputation Risk Is Exacerbating D&O Liability
• Monsanto Exec Named Bayer's US General Counsel
• Vioxx Economic Loss Counsel Win $4.2M In Attys' Fees
• McKesson Is Roped Into Generic-Drug Price-Fixing Row
• J&J Fights $245M Faulty Hip Implant Judgment
• PwC Escapes Valeant Investors' $80B Price-Gouging Suit
• Medco Exec Tells 3rd Circ. FCA Suit Based On Nonpublic Info
• 3 Firms Steer Alexion's Deal For VC-Backed Syntimmune
• Allergan Medicaid Rebate Suit Redo Denied At 3rd Circ.
• Brazilian Education Tech Co. Leads 4 IPOs Totaling $477M
• Express Scripts Overcharged Attys For Records, Suit Says
• 3rd Circ. Won't Revive Chinese Co.'s GSK Probe Suit
• Expert's Analyses Questioned In AbbVie Merger Cert. Row
• 2 Firms Steer Automation Co.'s $450M Genomics Buy
• Doctor DQ'd From Testifying About Opioids In Insys Case
• SEC Fires Warning Shot Against 'Short And Distort' Schemes
• Federal Courts Diverge On Bristol-Myers And Class Actions
• 5 More GC Tips For Succeeding As A New Associate
• Atty Lies Shouldn't Doom $200M IP Win, Merck Tells Justices
• USPTO Patent-Eligibility Revamp May Face Court Skepticism
• Opko Faces Wave Of Suits After SEC Pump-And-Dump Claims
• Hartig Seeks $3M In Attys' Fees In Product-Hopping Suit
• 'IV Cocktail' Ads Stir FTC To Prioritize Health Enforcement
• Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield
• FTC Wins False Ad Suit Against Diet Pill Maker Roca Labs
• Investor Sues KMG Chemicals To Block $1.6B Cabot Merger
• Roche Escapes Stock-Drop Suit Over Cancer Drug Results
• Judging A Book: Block Reviews 'Tough Cases'
• Ex-NFLer Can't Ditch Pump-And-Dump Verdict At 9th Circ.
• Roundup MDL Seeks More NorCal Bellwether Cases For Trial
• Prosecutors Can Tell 3rd NECC Jury About Meningitis Pain
• Jury Deadlock Ends Latest Philly Mesh Case
• EHealthline.com Says $3.5M Award Row Should Be Paused
• Humira Kickback Claims Spawn Investor Suit Against AbbVie
• Amarin Sees Off-Label Claims Boosted By Study Results
• Janssen Gets $1M Risperdal Breast-Growth Verdict Flipped
• Communication Is Key To Quick ANDA Approvals, FDA Says
• Sanofi Allowed To Scrap Pain Cream Contract, Judge Says
• Vitamin C Importers Tell 2nd Circ. Price Fixing Voluntary
• Ex-Akebia Analyst Jailed For Ignoring Probation Calls
• Jury Deadlocks In J&J Trial Over Talc-Asbestos Claim
• Allergan's Discovery Buck-Passing Rejected In Opioid MDL
• Cancer Test Maker, Biotech Firm Prime IPOs Totaling $326M
• US-China Fight Shows No Sign Of Stopping As New Tariffs Hit
• 8 Innovative Ways To Empower Jurors
• PTAB Upholds Alcon Patent For Glaucoma Treatment
• 15 Firms To Lead IPOs Exceeding $1.1B Amid Peak Season
• Athenex Gets FDA Compounding Policy Wrong, Amicus Says
• Health Hires: DLA Piper, Baker Donelson, Pharma GCs
• Consumer Seeks Full 3rd Circ. Redo Of Toxic Talc Ruling
• Allergan, Tribe Sue Pharma Co. Over Restasis Patent
• Atty Can't Shake $1.76M Suit Over Alleged Consulting Scam
• MabVax Stock Actions Stand Amid Pump-And-Dump Claims
• Sterigenics Hid Cancer Risk Of Emissions, Ill. Residents Say
• Class Attys Get $35M Of $105M Lidoderm Pay-For-Delay Deal
• Fosamax MDL Revival Must Be Nixed, US Tells High Court
• Wage-And-Hour Suit Against J&J Headed Back To State Court
• Cloud Computing Clearly The Future For Small Firms
• Telemedicine — The Next Frontier For DOJ Scrutiny?
• New MDL Needed For 'Opioid Babies,' Attys Say
• CORRECTED: Attys Sanctioned $655K After $645M Medical Device Row Loss
• Counsel Needs 'Backup' For Payment In $4.75M Vertex Deal
• 7th Circ. Will Not Rehear Suit Against GSK Over Atty's Suicide
• FTC Settles With 'IV Cocktail' Seller Over Health Claims
• Houston Pill Mill Doc, Clinic Chief Each Get 35 Years In Prison
• J&J Can't Escape Calif. Talc Warning Label Suit
• Purdue Pharma Must Face NH's Suit Over Opioid Marketing
• Leveraging Today's Lateral Associate Market
• Opioid Bill Lacks Funding To Make Lasting Impact
• 'One A Day' Will Not Keep Plaintiffs Away
• Trustee Objects To Debt Forgiveness In ActiveCare's Ch. 11
• UnitedHealthcare Can't Take Back Cephalon Antitrust Deal
• AngioDynamics Says Rival Must Stay In $145M Damages Row
• Mass. Doc Dodges Prison After Giving Patient Info To Drug Co.
• Pfizer Unit, Teva Must Face Effexor Antitrust Litigation
• SEC Accuses Breast Implant Maker's Ex-CEO Of Stock Fraud
• Eli Lilly's Animal Health Unit Elanco Raises $1.5B In IPO
• No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears
• Deals Rumor Mill: Tencent Music, Linde, Coca-Cola
• FDA Warning Wire: Beer Brewing At Lab, Mice At Egg Giant
• Allergan Loses 'Meritless' Bid To Gut Restasis Antitrust MDL
• French Medical Device Maker Sued Over Clot Filter Failure
• Patents At The High Court: What To Watch In The New Term
• US Finalizes Hefty Tariffs On Chinese Sodium Compound
• Novartis Warping Kickback Standard In FCA Case, DOJ Says
• Back To School: Stanford's Jeff Fisher Talks Supreme Court
• Genetic Data Holds Opportunities And Risks For Litigants
• Monsanto Fights To Get $289M Verdict Tossed Or A New Trial
• Merck Workers Defend Class Claims In $250M Sex Bias Suit
• Boston Scientific Faces Chancery Suit For Ending $275M Deal
• 2 Risperdal Cases Greenlighted For Punitive Damages Trials
• Labaton, Levi Vie For Lead Role In Prothena Stock-Drop Row
• AbbVie Kickbacks Tainted $1.3B In Humira Claims, Calif. Says
• Ulthera Appeals PTAB Decision Upholding Skin Care Patent
• 7th Circ. Has Chance To Cut Off 'Mootness Fee' Merger Cases
• J&J Cut Corners, Pelvic Mesh Jury Hears At Philly Trial's End
• Deals Rumor Mill: GSK, ADC Therapeutics, Haidilao
• Fed. Circ. Ruling Takes 'Blocking Patents' To New Places
• Clovis To Pay $20M To End SEC Claims Over Cancer Drug
• Six Cos. Launch IPOs Totaling $465M Led By Biotech Firms
• Ore. Pot Biz Owner Gets 7 Months For Federal Tax Crimes
• Biotech Cos. Must Respect Coexisting Gene Editing Patents
• SEC Settles With Alleged Chicago Penny Stock Fraudster
• Orexigen Decision At Odds With High Court Jurisprudence
• Smith & Nephew To Pay $10.5M To Settle Knee Implant IP Row
• No Kickback Fines For Implant Refunds, HHS Watchdog Says
• Biopharm Co. Investors Sue Directors In Chancery Over Pay
• J&J Talc Supplier Makes Last-Second Deal In Asbestos Trial
• J&J Wages New Fight Over Asbestos In Talc After $117M Loss
• Deals Rumor Mill: Uber, Bayer, QIA
• Opioid MDL Stakes Rise For Pharmacy Benefit Cos.
• Armstrong Teasdale Heads Into Philly With Montgomery Chair
• Gleevec Buyers Say 1st Circ.'s Dismissal Misread Patent Law
• Insys Wants Out Of Off-Label Fentanyl Prescription Suit
• Court Sanctions Nutrition CEO, Atty Over False Patent Claims
• Sport Supplement Co., Consumers Settle Deceptive Label Suit
• What Manufacturers Should Know About Triclosan Findings
• Teva Looks To Escape Proposed Price-Hike Class Action
• Valeant Must Face Deceptive Pricing Claims By Hedge Funds
• Calif.'s New Rules For Lawyers Move Closer To ABA Model
• Surveying The Cannabis Patent Litigation Landscape
• J&J Hit With Another Suit Over Alleged Talc-Related Death
• 14 Firms To Steer 8 IPOs Topping $3B As Busy Autumn Nears
• 2nd Ex-GSK Scientist Pleads Guilty In Chinese IP Theft Case
• Justices Told FDA's 'Smoking Gun' Sinks Fosamax MDL
• WilmerHale, Cooley Guide $100M Biotech IPOs
• McCarter & English Nabs Gibbons Product Liability Pro In NJ
• Biopharma Co. Principia Leads 3 IPOs Totaling $225.3M
• Takeda's £46B Shire Buy Gets Nod From Chinese Regulator
• FTC Told Impax Can't Justify Opana Reverse Payment
• Valeant, PwC Shed State Law Claims In Investors' Suit
• FDA Focus: What Axinn's Practice Chair Is Watching
• Relators Slam Teva's Quick Win Bid In Overpaid Speaker Suit
• Congressional Forecast: September
• Know The Limits To Atty Public Statements During A Trial
• J&J Must Pay $29M For Selling Talc With Asbestos, Jury Told
• Boston Joins In Suing Purdue, Others Over Opioid Epidemic
• FDA Never Saw Birth-Defect Tests On GSK Drug, Families Say
• Fed. Circ. Backs PTAB, Says Inventor's Catalog Dooms Patent
• Boehringer Snags Austrian Biopharma Co. In $245M Deal
• Allergan Looks To Keep CEO's Tribal Patent Docs Out Of MDL
• Deals Rumor Mill: Meituan Dianping, Takeda, Adobe Systems
• FTC's Public Hearings Will Be Valuable
• In Calif., Questions Remain On Law Firm Conflict Waivers
• A Chat With Faegre Client Development Chief Melanie Green
• DOJ Is Getting Creative, And Aggressive, On Opioids
• Trump Not In A Hurry To Broker Trade Peace With China
• Two Lidoderm Class Action Deals Worth $271M Get Final OK
• SEC Claims Mass. Broker Lied To Short Drug Co. By $1.3M
• Medline's Docs Not False, Judge Says In Catheter Design Row
• Law Schools Struggle To Find Themselves In Post-Recession Market
• Bausch Health, Actavis Strike Deal Over Generic Xifaxan
• Intuitive Surgical Investors Strike $42.5M Stock-Drop Deal
• Conflict Should DQ Katten In IP Row, Valeant Tells Fed. Circ.
• McDermott Snags Ex-HHS OIG Pro As Partner For DC Office
• Medical Co. Investors Want Final $5M Deal OK'd In IPO Row
• 1st Circ. Questions BioChemics Strategy In SEC Probe Case
• Intellectual Property Caught In US-China Trade Crossfire
• How A 'Lost Generation' Of Associates Bounced Back
• CRISPR Patent Ruling May Push Warring Sides To A Deal
• Hospitals Sue HHS For Slow-Walking 340B Penalties
• Out-Of-State J&J Talc Suits Tossed From Delaware Courts
• OTC Health Products Maker Hits Ch. 11 In Wake Of Recalls
• FDA Warning Wire: Plant Problems Behind Medtronic Recalls
• Judge Ends Bayer Battle Over 'Flanax' Trademark
• FDA's Former Top Atty Heads Back To Sidley Austin
• BioChemics Claims It Can Pay Chunk Of $17M SEC Judgment
• Akorn FDA Report Added To Fresenius Trial Record
• ResMed Rival Returns Fire In Sleep Aid Patent Battle At ITC
• Fla. Doc Gets 20 Years For 'Hospice-Level' Opioid Scripts
• Bristol-Myers Looks To Ax Investor Suit Over Clinical Trial
• Dechert Adds Life Sciences-Focused PE Atty In London
• Asbestos-In-J&J Talc Claims Withdrawn On Eve Of Trial
• Medical Device Maker Wins $645M In Rival Theft Case
• AbbVie Strikes Tentative Deal In Testosterone MDL
• Consumers Denied Cert. In False Ad Suit Over Diet 'Crystals'
• Akorn Says FDA Report Rehashes Data From Fresenius Trial
• Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents
• Can BigLaw Avoid Another Associate Purge?
• 8th Circ. Backs $25K Atty Sanction In Enbrel Discovery Row
• NJ Doc Loses License Over Opioid Prescriptions, Insys Pay
• China Tells 2nd Circ. Vitamin C Exporters Followed Law
• Fed. Circ. Backs Harvard, MIT Over UC In CRISPR Patent War
• Fed. Circ. Revives Orexo's Opioid Addiction Treatment Patent
• Imprimis Sanctioned Again For Flouting Discovery Order
• Muscle Milk Buyers Get Partial Cert. In Nutrition Labeling Row
• Why State Marijuana-Impaired Driving Laws Need Reform
• When Courts Allow Changes To Hatch-Waxman 30-Month Stay
• Has BigLaw Recovered From The Financial Crisis?
• Measuring The Recession's Toll On The Legal Industry
• Ex-Teva Head Accused Of Role In $27M Pump-And-Dump Scheme
• Biogen Gets Win In Drug IP Fight As Judge Overrides Jury
• Impax Escapes Investors' Drug Price-Fixing Suit, For Now
• Suit Over Bayer's Twice-Daily 'One A Day' Gummies Revived
• Pipe Giant Tops 3 IPO Launches Surpassing $1B Combined
• States Back Tribe, Allergan Fed. Circ. Bid For PTAB Immunity
• Brand Battles: Hot Pockets, Adderall, Superman
• As Biz Opposes China Tariffs, Trump Says More On The Way
• Real Estate Rumors: Deutsche Bank, Citi, Allergan
• Health Hires: Pepper Hamilton, Perkins Coie, Davis Wright
• BTG Snags Irish Vascular Health Co. In $150M Deal
• St. Jude Ditches Patient's Defective Heart Valve Suit
• Amgen Suit Shows Limitations Of Biosimilar Safe Harbor
• Boston Biotech Exec Cops To Role In $12.7M Painkiller Fraud
• A Look At OIG's Medicare Exclusion Analysis Under FCA
• 3rd Circ. Says 'Buyer's Remorse' Can't Revive Toxic Talc Suit
• Church & Dwight Wins $10M In Pregnancy Test False-Ad Suit
• Reed Smith Widow Wants Full 7th Circ. To Consider GSK Suit
• Mylan Decries 'Hopeless Fishing Expedition' In EpiPen MDL
• The Bloody Saga That Made Theranos Finally Call It Quits
• Abiomed Seeks Quick Win In Fired Exec's $2.1M Equity Suit
• VC-Backed Upwork, Guardant File IPOs Totaling $200M
• Fed. Circ. Hands Win To Supernus Over Generic Seizure Drug
• Ex-Celator Employee Gets Prison For Insider Trading Scheme
• Monsanto Can't Round Up Chemical Docs From Advocacy Org
• Mylan Investors Push Back At Bid To Toss EpiPen Claims
• Ex-Akebia, Merrimack Analysts Want Conviction Tossed
• Oberland Capital Reaps $800M For Second Fund
• Lilly's Animal Health Unit Gears Up To Launch $1.4B IPO
• Ice Miller Welcomes Ex-Robinson Brog Partner In New York
• 7th Circ. Mulls Lack Of State Action In Fetal Tissue Law Row
• Lens Makers Fight Sanctions Over Defunct Facebook Page
• Gwyneth Paltrow's Co. Settles Vaginal Egg Health Claims Suit
• Tribes Can't Have Opioid Suits Sent To State Court From MDL
• Bio-Focused VC Firm Westlake Scores $320M 1st Fund
• Wine Spectator Hits 'Weed Spectator' With Trademark Suit
• PTAB Stands By Post-SAS Changes In Dartmouth Patent Case
• J&J, Janssen Win Mass. Risperdal Suit On Teen's Weight Gain
• Chinese News Aggregator Sets Price Range For IPO
• FDA Focus: What Morgan Lewis' Practice Chair Is Watching
• Getinge Dodges Subsidiary's Blood Pump Patent Fight
• 3rd Circ. Revives FCA Case Against PharMerica
• Feds Fight Claim That Expert Witness Double-Crossed Insys
• Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win
• Withers Lands Ex-Bryan Cave Arbitration Pro In NY
• McKesson Defends Right To $7M Of Disputed Orexigen Funds
• Yaz MDL Lead Attys Dodge Breach Of Fiduciary Duty Claim
• Shkreli Claims Bad Jury Instructions In 2nd Circ. Appeal
• ResMed Asks ITC, Calif. Court To Block Import Of Sleep Aids
• Court Can't Block Nonfinal Compounding Policy, FDA Says
• Back To School: Widener's Rod Smolla Talks Free Speech
• Tribe Can't Fault Generics Cos. For Opioid Crisis, Court Told
• Teva Worker's Discrimination Suit Stays Alive In Pa.
• Sanofi Settles SEC's International Bribery Claims For $25M
• J&J Loses Pa. Rehearing Bid Over Out-Of-State Mesh Cases
• 1st Circ. Eye Drop Decision Gets Preemption Right
• Treatment Method Patents After Fed. Circ. Vanda Ruling